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Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hepatitis C 
virus (HCV) serogroup 1 infection.  We studied the efficacy of this therapy by focusing on the factors associated 
with sustained virological responses (SVR) including resistance-associated variants (RAVs) and mixed infection 
of different HCV genotypes.  We enrolled 951 HCV serogroup 1-positive patients who received this combina-
tion therapy at our hospital or affiliated hospitals.  The presence of RAVs in non-structural (NS) regions 3 and 
5A was analyzed by direct sequencing.  HCV genotypes were determined by PCR with genotype-specific prim-
ers targeting HCV core and NS5B regions.  SVR was achieved in 91.1% of patients.  Female sex,  age > 70 years,  
and RAVs were significantly associated with non-SVR (p< 0.01 for all).  Propensity score-matching results 
among the patients without RAVs regarding sex,  age,  and fibrosis revealed that mixed HCV infection deter-
mined by HCV NS5B genotyping showed significantly lower SVR rates than 1B-mono infection (p= 0.02).  
Female sex and RAVs were significant factors associated with treatment failure of this combination therapy for 
patients with HCV serogroup 1 infection.  Mixed HCV infection other than 1B-mono infection would be useful 
for predicting treatment failure.
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H epatitis C virus (HCV) is a single-stranded RNA virus,  and HCV infection is transmitted mainly 
through blood [1].  Chronic hepatitis C (CHC) is one of 
the most common liver diseases.  CHC patients often 
develop liver cirrhosis (LC),  and each year,  hepatocel-
lular carcinoma (HCC) is detected in 1～4% of LC 
patients [1].  Eradication of HCV is important to sup-
press progression to LC or HCC.
In 2014,  Japan started implementing treatment for 
HCV eradication with direct-acting antivirals (DAAs) 
using the combination of asunaprevir (ASV),  a non- 
structural 3 (NS3) protease inhibitor,  and daclatasvir 
(DCV),  an NS5A replication complex inhibitor.  Similar 
treatments have been used globally because of their 
high therapeutic efficacy and mild adverse events com-
pared to interferon-based therapy [2 , 3].  It was 
reported that HCV variants associated with DAA resis-
tance (i.e.,  resistance-associated variants,  RAVs) 
strongly affect the non-virological response [4].  
However,  some patients without RAVs cannot achieve 
sustained virological responses (SVR).  The factors 
associated with non-SVR other than RAVs must be clar-
ified.
ASV is effective against HCV genotype 1B but is not 
as effective against other HCV genotypes.  It remains 
unclear whether a mixed infection of different HCV 
genotypes other than 1B affects therapeutic outcomes of 
patients treated with DCV + ASV combination therapy.  
We thus conducted the present study with a focus on 
mixed infection of different HCV genotypes,  and we 
investigated whether mixed infection of different HCV 
genotypes is associated with non-sustained virological 
response to DCV + ASV combination therapy.
Patients and Methods
Patients and treatment. We consecutively enrolled 
951 HCV serogroup 1-positive patients with CHC or LC 
who received DCV + ASV combination therapy at 
Okayama University Hospital and its affiliated hospitals 
from March 2012 to September 2015.  Patients with 
HCC,  hepatic failure,  and coinfection with hepatitis B 
virus or human immunodeficiency virus were excluded 
from the study.  None of the patients received previous 
antiviral therapy with DAAs.  Cirrhosis was determined 
via blood testing or imaging at enrollment.  This study 
was performed in accordance with the Helsinki 
Declaration,  and the protocol was approved by the eth-
ics committee of the institute (approval No. 2258).  This 
study was registered in the University Hospital Medical 
Information Network Clinical Trials Registry (UMIN 
000001031).  All patients provided informed consent 
before enrollment.  DCV was administered orally at a 
dose of 60 mg 1×/day for 24 weeks and ASV was admin-
istered orally at a dose of 100 mg 2 × /day for 24 weeks.
Measurement of RAVs. Serum RNA was extracted 
using the QIAamp Viral RNA Mini Kit (Qiagen,  Tokyo,  
Japan) according to the manufacturer’s protocol.  cDNA 
was synthesized from the extracted RNA using 
Superscript II (Thermo Fisher Scientific,  Tokyo,  Japan) 
with random hexamers,  and was amplified by poly-
merase chain reaction (PCR) using primers targeting 
HCV NS3 and NS5A regions [5].  Direct sequencing 
was performed using the Big Dye Terminator Cycle 
Sequencing kit (Applied Biosystems,  Foster City,  CA,  
USA) on an ABI Prism 310 genetic analyzer (Applied 
Biosystems).  The drug-resistant mutations D168A,  
D168E,  D168H,  D168T,  and D168V in the HCV NS3 
region and L31F,  L31M,  L31V,  and Y93H in the HCV 
NS5A region were alternatively assessed in some 
patients using direct sequencing or the PCR-invader 
assay (BML,  Tokyo,  Japan),  which is a real-time PCR 
detection system with a site-specific and control com-
ponent [5 , 6].  Significant mutation was considered to 
exist when > 10% of RAVs was confirmed by direct 
sequencing or when the invader assay demonstrated a 
strong positive result.  Patients with RAVs did not 
receive DCV + ASV combination therapy as a principle 
until the advent of next-generation therapy.  Some 
patients with LC and some patients after curative treat-
ment for HCC received this treatment upon their 
request.
Single nucleotide polymorphism (SNP) genotyping.
Single nucleotide polymorphism (SNP) rs8099917 of the 
interleukin-28b gene (IL28B) was determined as 
described [5].  Briefly,  genomic DNA was extracted 
from whole blood samples using a QIAamp DNA Mini 
Kit (Qiagen) according to the manufacturer’s protocol.  
The rs8099917 genotype was determined using the 
TaqMan pre-designed SNP genotyping assay (Applied 
Biosystems) with the LightCycler 480 system (Roche 
Diagnostics,  Tokyo,  Japan).  The SNP genotypes of all 
samples analyzed in this study were obtained using this 
assay.
Determination of HCV genotype in core and NS5B 
regions. Serum RNA was extracted using the 
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QIAamp Viral RNA Mini Kit (Qiagen) according to the 
manufacturer’s protocol.  cDNA was synthesized from 
the extracted RNA using Superscript II (Thermo Fisher 
Scientific) with random hexamers.  A PCR with geno-
type-specific primers targeting the HCV core region 
was subsequently performed for HCV core genotyping,  
as described: briefly,  the first PCR used the common 
primer-set for the cDNA amplification of all of the gen-
otypes,  and the second PCR was done separately with 
the individual genotype-specific primers [7].  In cases 
with the results of mixed infection by HCV core geno-
typing,  a PCR was done with the mixture of all of the 
genotype-specific primers for HCV core genotyping.  
For HCV NS5B genotyping,  a PCR with genotype-spe-
cific primers targeting the HCV NS5B region was per-
formed as described; both the first and second PCRs 
were done with the mixture of all of the genotype-spe-
cific primers [8].  Agarose gel electrophoresis was con-
ducted to detect the expected DNA fragment size for 
each genotype.
Determination of HCV serogroup in the NS4 region.
The HCV serogroup was determined by detecting anti-
bodies against group-specific recombinant proteins in 
the putative NS4 protein region (amino acids [aa] 
1676-1760) with an enzyme-linked immunosorbent 
assay (HCV serotype,  BML).  This region of the HCV 
peptide has many group-specific amino acids [9].
Statistical analysis. We analyzed factors associ-
ated with treatment outcomes by performing a multi-
variate logistic regression analysis.  The propensity score 
was estimated for each patient without RAVs using this 
logistic regression model for age,  sex and fibrosis,  
which were the factors identified as correlating with 
non-SVR.  The patients with treatment failure were 
matched with those obtaining an SVR.  A caliper width 
within 0.1 of the propensity score was applied for 
matching.  We analyzed the influence of mixed infection 
of different HCV genotypes on treatment outcomes by 
using the chi-squared test or Fisher’s exact probability 
test.  Statistical analyses were performed using JMP Pro 
ver. 12.0 (SAS Institute,  Cary,  NC,  USA),  and p-val-
ues < 0.05 were considered significant.
Results
Patient characteristics and virological response.
As shown in Table 1,  the median patient age was 71 
years (range,  24-90 years).  Of the patients whose IL28B 
SNP genotypes were assessed,  303 patients (62.2%) had 
the major allele (TT),  and 184 patients (37.8%) had the 
minor allele (GG or TG).  Approximately one-third of 
the patients were diagnosed with compensated LC.  
Fifty-six patients had RAVs of aa168 in the HCV NS3 
region,  and 63 patients had RAVs of aa31 or aa93 in the 
HCV NS5A region (Table 1).  As shown in Fig. 1A,  
serum HCV RNA disappeared rapidly (i.e.,  within 4 
weeks of the start of the treatment) in 740 patients 
(79%) and within 12 weeks of the start of treatment in 
881 patients (97%) and/or remained undetectable by the 
end of the treatment period in 904 patients (95%).  A 
total of 866 patients (91%) achieved SVR at 12 weeks of 
treatment (SVR12),  and viral relapse was observed in 
47 patients (4.9%).  Treatment was discontinued in 117 
patients due to viral breakthrough (VBT) or non-viro-
logical response (NVR) in 47 patients and to adverse 
events in the other 70 patients.
Factors associated with treatment outcomes.
Significant factors associated with SVR12 were male sex 
and no RAVs (p < 0.0001 for both,  the chi-square test) 
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Table 1　 Patient characteristics
Factors
Age (years) 71 (24-90)
Sex (male/female) 449/502
IL28B SNP rs8099917 (TT/TG/GG) 303/170/14
Previous interferon treatment
(none/relapse/non-response/intolerance/
non-SVR)
417/98/225/56/155
Fibrosis (chronic hepatitis/liver cirrhosis) 618/333
Platelet count (×104/µL) 12.8 (2.6-43.7)
Aspartate aminotransferase (IU/L) 43 (15-260)
Alanine aminotransferase (IU/L) 37 (6-352)
Albumin (g/dL) 4.0 (2.3-5.2)
Total bilirubin (mg/dL) 0.7 (0.2-2.9)
Alpha-fetoprotein (ng/mL) 6.0 (0.8-776)
HCV RNA (log IU/mL) 6.1 (1.7-7.5)
NS3 aa168 (D/A,  E,  H,  T,  or V) 622/56
NS5A aa31 (L/F,  M,  or V) 770/20
NS5A aa93 (Y/H) 785/43
(Fig. 1B, 1C).  The SVR12 rates showed no significant 
difference in terms of age,  IL28B SNP genotype,  LC,  or 
previous interferon treatment.  The multivariate logistic 
regression analysis of all patients for non-SVR showed 
that RAV,  female sex,  and elderly patients were signifi-
cant factors associated with non-SVR (p= 0.003 , 0.0005 ,  
and 0.0009,  respectively) (Table 2).  Among only the 
patients without RAVs,  female sex was the only signifi-
cant factor associated with non-SVR (p = 0.0001) (Table 
3).  The female patients were significantly older than the 
male patients (p = 0.0013).  Therefore,  old age was con-
sidered a confounding factor in female patients.
Associations of mixed infection of different HCV 
genotypes with treatment outcomes. We determined 
the HCV genotypes by a PCR with genotype-specific 
primers targeting the HCV core and NS5B regions for 
129 patients without RAV,  including 86 patients who 
achieved SVR12,  13 patients with viral relapse after 
treatment,  18 patients with NVR or VBT,  and 12 
patients with treatment cessation (Table 4).  Mixed 
HCV infection of genotype 1B and other genotypes was 
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Table 2　 Multivariate logistic regression analysis of factors asso-
ciated with treatment failure in all patients enrolled in the study
Cut-oﬀ Odds ratio 95%CI p
Age (years) ＜70 3.0 1.4-6.6 ＜0.01
Sex Female 3.8 1.8-9.0 ＜0.01
IL28B SNP Minorgenotype 1.6 0.8-3.3 0.18
RAV Resistanttype 3.7 1.7-7.6 ＜0.01
Fibrosis Livercirrhosis 1.4 0.68-2.9 0.36
Fig. 1　 Patients with undetectable HCV RNA (%) 
during treatment.  A,  The rates of patients with unde-
tectable HCV RNA at 4 weeks of treatment,  12 weeks 
of treatment,  end of treatment (EOT),  and 12 weeks 
after treatment (SVR12).  Only the patients with ≥4 
weeks of treatment (n＝942) were included for the 
analysis of the rate of undetectable HCV RNA at 4 
weeks of treatment,  and the rate at 12 weeks of treat-
ment was calculated with only the patients with ≥12 
weeks of the treatment (n＝904); B,  The SVR rates 
classiﬁed by age,  sex,  and IL28B SNP genotype; C,  
The SVR rates classiﬁed by ﬁbrosis,  previous interferon 
treatment,  and RAV.
detected in 31 patients by HCV core genotyping: HCV 
1A and 1B in 20 patients; HCV 1B and 2A in 7 patients;  
HCV 1B and 2B in 2 patients; and HCV 1A,  1B,  and 
2A in 2 patients.  The second PCR with the mixture of 
all of the genotype-specific primers detected HCV 1B 
only for those patients with the results of mixed HCV 
infection of HCV 1A and 1B.  Mixed HCV infection of 
genotype 1B and other genotypes was detected in 5 
patients by HCV NS5B genotyping: HCV 1A and 1B 
in 3 patients and HCV 1B and 2B in 2 patients.  One 
patient showed mixed HCV infection in both HCV core 
and NS5B regions.  All 5 of the patients with mixed 
HCV infection of genotype 1B and other genotypes by 
HCV NS5B genotyping were female; one patient com-
pleted treatment and achieved SVR12,  while the 
remaining 4 patients had NVR or VBT.  Only one 
patient with mixed HCV infection of genotype 1B and 
other genotypes by HCV NS5B genotyping obtained 
SVR12 (20.0%),  and this SVR12 rate was significantly 
lower than the SVR12 rate in the patients with HCV 1B 
mono-infection by HCV NS5B genotyping (76.6%,  
p = 0.015,  Fisher’s exact probability test) (Fig. 2A).  We 
evaluated this tendency in the comparison of the SVR 
and non-SVR patient groups by propensity score- 
matching.  The baseline characteristics of the propensity 
score-matched patient groups achieving SVR and non-
SVR were almost identical as those of the patients with 
IL28B SNP genotypes and previous interferon treatment 
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Table 3　 Multivariate logistic regression analysis of factors asso-
ciated with treatment failure in all patients without RAV
Cut-oﬀ Odds ratio 95%CI p
Age (years) ＜70 1.9 0.85-4.6 0.12
Sex Female 6.2 2.3-21.6 ＜0.01
IL28B SNP Minorgenotype 0.93 0.38-2.2 0.88
Fibrosis Livercirrhosis 1.3 0.54-2.9 0.57
Table 4　 Characteristics of patients assessed by HCV genotyping
Factors All (N＝129) SVR (n＝66) Non-SVR (n＝33) p
Age (years) 72 (33-88) 73 (48-88) 69 (33-81) 0.13
Sex (male/female) 33/66 22/44 11/22 1.00
IL28B SNP rs8099917
(TT/TG or GG) 76/47 40/18 14/9 0.49
Fibrosis
(chronic hepatitis/liver cirrhosis) 59/40 39/27 20/13 0.88
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Fig. 2　 Sustained virological 
response (%) classiﬁed by HCV gen-
otype.  A,  The SVR rates among all 
patients without RAVs; B,  The SVR 
rates among patients without RAVs 
selected by propensity score-match-
ing.
(Table 4).  The result showed that mixed HCV infection 
of different HCV genotypes by HCV NS5B genotyping 
was significantly associated with non-SVR (p = 0.02) 
(Fig. 2B).
Discussion
The development of interferon-free regimens with 
oral DAAs has dramatically changed the treatment 
strategy for CHC.  Viral fitness against antiviral drugs 
and the emergence of drug RAVs remain a challenge for 
treatment with oral DAAs [4 , 5].  Concerning DCV +  
ASV combination therapy,  mixed HCV infection of 
genotypes other than genotype 1B is thought to affect 
therapeutic outcomes because ASV is effective against 
HCV genotype 1B but is not as effective against other 
HCV genotypes.  We therefore analyzed factors associ-
ated with non-SVR with a focus on mixed infection of 
different HCV genotypes.  Our findings revealed that 
mixed infection of different HCV genotypes,  in addi-
tion to RAV,  affects the treatment failure of DCV + ASV 
combination therapy.  Our analyses also showed that 
RAV and female sex were significantly associated with 
non-SVR.
Since HCV genotypes are usually assessed by geno-
typing HCV in the core region,  we speculated that the 
HCV genotype in the NS region may affect the viral 
fitness against antiviral drugs and should be evaluated 
for potential associations with treatment outcomes of 
DAA therapy.  We thus determined the HCV genotype 
in both structural and non-structural regions and eval-
uated the associations of the HCV genotype in struc-
tural and non-structural regions with treatment out-
comes.  Our results demonstrated that mixed HCV 
infection determined by genotyping in the non-struc-
tural region was significantly associated with the treat-
ment failure of DCV + ASV combination therapy,  but 
this association was not observed in mixed HCV infec-
tion determined by genotyping in the structural region.  
As shown by our results,  the higher detection rate of 
mixed HCV infection by genotyping HCV in the core 
region compared to that by genotyping HCV in the 
NS5B region might occur because of the independent 
use of genotype-specific primers in the second PCR of 
the HCV core genotyping; minor HCV populations 
could be detected.  Genotyping HCV in the NS5B 
region uses the mixture of all of the genotype-specific 
primers in the second PCR,  detecting only major HCV 
populations.  A minor population of HCV infections 
can be assessed by next-generation sequencing with the 
independent use of genotype-specific primers.  Another 
possibility is that 1B-HCV might be amplified with 
1A-specific primers because of an insufficient specificity 
of genotype-specific primers.
In conclusion,  female sex and RAVs were significant 
factors associated with the treatment failure of DCV +  
ASV combination therapy for patients with HCV sero-
group 1 infection.  Mixed HCV infection other than 
1B-mono infection would be useful for predicting treat-
ment failure.
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